This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palomba, S. Articles by Zullo, F. Search for Related Content PubMed PubMed Citation Articles by Palomba, S. Articles by Zullo, F.

Raloxifene Administration in Premenopausal Women with Uterine Leiomyomas: A Pilot Study

Chair of Obstetrics and Gynecology (S.P., M.M., T.R., F.Z.), University of Catanzaro, 88100 Catanzaro; Department of Molecular and Clinical Endocrinology and Oncology (F.O., G.L.), University of Naples "Federico II", 80131 Naples; Department of Gynecology, Obstetrics, and Human Reproduction (M.P., C.N.), University of Naples "Federico II", 80131 Naples; Chair of Obstetrics and Gynecology (E.Z.), University "Tor Vergata" of Rome, 72100 Rome; and Chair of Obstetrics and Gynecology (P.L.B.P.), University of Rome "Campus Biomedico", 72100 Rome, Italy

Address all correspondence and requests for reprints to: Dr. Stefano Palomba, Via Nicolardi 188, 80131 Napoli, Italy. E-mail: . stefanopalomba{at}tin.it

Abstract

This prospective randomized single-blind placebo-controlled clinical trial was carried out to evaluate the effects of raloxifene administration on uterine and leiomyoma sizes in premenopausal women. Ninety healthy premenopausal women affected by asymptomatic uterine leiomyomas were enrolled and treated with raloxifene at the doses of 60 mg/d (group A), 180 mg/d (group B), or placebo (group C). The duration of the treatment was 6 cycles of 28 d each.

At entry and after three and six cycles, uterine and leiomyoma sizes were measured by transvaginal ultrasonography. The difference between uterine and leiomyoma volumes ( size) was calculated in all subjects. The characteristics of the menstrual cycles and the side effects of the treatments were recorded using a daily diary. The severity of the uterine bleedings was assessed using a rank scale.

Throughout the study, no significant changes were observed in uterine and leiomyoma size or in size among the three groups and within each group of treatment. The length and severity of uterine bleedings was not significantly different between the three groups and within each group.

In conclusion, raloxifene has no significant effect on uterine and leiomyoma size or on menstrual cycle in premenopausal women.

This article has been cited by other articles:

				J. Liu, H. Matsuo, Q. Xu, W. Chen, J. Wang, and T. Maruo Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro Hum. Reprod., May 1, 2007; 22(5): 1253 - 1259. [Abstract] [Full Text] [PDF]

				J. A. Rivera, S. Christopoulos, D. Small, and M. Trifiro Hormonal Manipulation of Benign Metastasizing Leiomyomas: Report of Two Cases and Review of the Literature J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3183 - 3188. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, C. Nappi, P. Mastrantonio, G. Lombardi, A. Colao, and F. Zullo Raloxifene Administration in Women Treated with Gonadotropin-Releasing Hormone Agonist for Uterine Leiomyomas: Effects on Bone Metabolism J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4476 - 4481. [Abstract] [Full Text] [PDF]